Clinical Trial Update: Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluated obatoclax with bortezomib for relapsed or refractory multiple myeloma. The study was terminated and results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Obatoclax (obatoclax mesylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2013-12-09